Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Aquarius Surgical Technologies Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Lorne MacFarlane

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	14.9yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Lorne MacFarlane

14.9yrs

Görev süresi

Mr. Lorne Stewart MacFarlane serves as Chief Executive Officer at Aquarius Surgical Technologies Inc. since 2024. He served as the Chief Financial Officer of Metalo Manufacturing Inc. (alternate name : Mus...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Henniger	Independent Chairman of the Board	32.8yrs	Veri yok	Veri yok
Stanley Swierzewski	Independent Director	7.6yrs	Veri yok	Veri yok
Rajiv Singal	Director	less than a year	Veri yok	Veri yok
Charlotte Jansen	Director	less than a year	Veri yok	Veri yok

4.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: ASTI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Aquarius Surgical Technologies Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

First quarter 2025 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 1Q 2024)

Full year 2024 earnings released: CA$0.027 loss per share (vs CA$0.026 loss in FY 2023)

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 2Q 2023)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 3Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.011 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.037 loss per share (vs CA$0.079 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.016 loss in 1Q 2021)

Aquarius Surgical Technologies Inc. Announces Resignation of Gordon Willox as Director

President, CTO, MD & Director Gordon Willox has left the company

Third quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.016 loss per share

Full year earnings released - CA$0.076 loss per share

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi